logo
Inozyme Pharma Reports Full Year 2024 Financial Results and Announces Strategic Prioritization of ENPP1 Deficiency Pivotal Program and Recent Business Highlights

Inozyme Pharma Reports Full Year 2024 Financial Results and Announces Strategic Prioritization of ENPP1 Deficiency Pivotal Program and Recent Business Highlights

- Cash, cash equivalents and short-term investments as of December 31, 2024, and anticipated cost savings from prioritizing ENPP1 Deficiency program, including an approximately 25% workforce reduction, expected to support operations into the first quarter of 2026 -
- Enrollment complete in ENERGY 3 pivotal trial in pediatric patients with ENPP1 Deficiency; topline data expected in first quarter of 2026 -
- Positive interim results from ENERGY 1 trial and Expanded Access Program evaluating INZ-701 in infants and young children with ENPP1 Deficiency showed improvements from baseline in multiple measures of disease -
BOSTON, March 10, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) ('the Company' or 'Inozyme'), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today reported financial results for the full year ended December 31, 2024, and provided recent business highlights.
'2024 marked a transformative year for Inozyme as we achieved critical milestones in our ENPP1 Deficiency program that enabled us to complete enrollment in our pivotal ENERGY 3 trial and announce promising interim data in infants and young children with ENPP1 Deficiency in January 2025,' said Douglas A. Treco, Ph.D., CEO and Chairman of Inozyme Pharma. 'We are concentrating our resources on advancing INZ-701 toward potential approval in ENPP1 Deficiency. We believe this focus will allow us to most efficiently progress our lead program while building a strong foundation for future growth.'
Strategic Prioritization to Extend Cash Runway
As part of its recent strategic review, the Company has prioritized activities to support the planned Biologics License Application (BLA) filing for INZ-701 for the Company's lead indication, ENPP1 Deficiency. Patients with ABCC6 Deficiency being treated in the Company's long-term extension study, the Company's expanded access program, or under investigator-sponsored INDs will continue to receive treatment. Future trials in ABCC6 Deficiency and calciphylaxis will be postponed. These prioritization measures, which include a workforce reduction of approximately 25% of employees implemented in the first quarter of 2025, with the Company's cash, cash equivalents and short-term investments as of December 31, 2024, are expected to extend the Company's cash runway into the first quarter of 2026.
'The strategic refocusing of our portfolio necessitated difficult decisions, including a reduction in our workforce. These organizational changes, while challenging, are essential to extend our operational runway and maximize our ability to advance INZ-701 as a potential treatment for patients with ENPP1 Deficiency,' continued Dr. Treco. 'I want to express my deepest gratitude to every member of the Inozyme team, both those who will continue our mission and those who will be departing. Their exceptional dedication, talent, and passion have advanced our science and strengthened our commitment to patients with rare diseases.
Enrollment Complete in ENERGY 3 Pivotal Trial
In January 2025, the Company completed enrollment in its ENERGY 3 pivotal trial of INZ-701 in pediatric patients with ENPP1 Deficiency between the ages of one and less than 13 years across sites globally. With 27 patients enrolled, the trial's 2:1 randomized design provides >90% power to detect meaningful differences in radiographic global impression of change (RGI-C) between treatment and control groups. The Company anticipates completing the one-year dosing period for all patients by January 2026, with topline data expected in first quarter of 2026.
Positive Interim Data from the ENERGY 1 Trial and Expanded Access Program (EAP)
The Company recently announced positive interim data from the ENERGY 1 trial, involving three infants and the EAP, involving two infants and one 2.5-year-old child, which evaluated patients with generalized arterial calcification of infancy (GACI), a severe manifestation of ENPP1 Deficiency. Patients were treated with INZ-701 for periods of three weeks to 22 months. The data presentation can be accessed here on Inozyme's Investor Relations site.
Financial Results for the Year Ended December 31, 2024
Cash Position and Financial Guidance – Cash, cash equivalents, and short-term investments were $113.1 million as of December 31, 2024. Based on its current plans and including the recent strategic prioritization, the Company anticipates its cash, cash equivalents, and short-term investments as of December 31, 2024, will enable the Company to fund cash flow requirements into the first quarter of 2026.
Research and Development (R&D) Expenses – R&D expenses were $83.2 million for the year ended December 31, 2024, compared to $54.8 million for the year ended December 31, 2023. The increase of $28.4 million was driven by $14.9 million in clinical development and related consulting costs to support our ongoing clinical trials, $10.1 million in chemistry, manufacturing, and controls expense to support our ongoing clinical trials and prepare for potential commercialization, $3.9 million in personnel-related costs, including stock-based compensation expense, offset by a $0.5 million decrease in facilities administrative expense.
General and Administrative (G&A) Expenses – G&A expenses were $20.8 million for the year ended December 31, 2024, remaining consistent with the $20.8 million reported for the year ended December 31, 2023.
Net Loss – Net loss was $102.0 million, or $1.62 loss per share, for the year ended December 31, 2024, compared to $71.2 million, or $1.37 loss per share, for the year ended December 31, 2023.
About ENPP1 Deficiency
ENPP1 Deficiency is a serious and progressive rare disease that affects blood vessels, soft tissues, and bones. Individuals who present in utero or in infancy are typically diagnosed with generalized arterial calcification of infancy (GACI Type 1), with about 50% of these infants not surviving beyond six months. Children with this condition typically develop autosomal-recessive hypophosphatemic rickets type 2 (ARHR2), while adolescents and adults may develop osteomalacia, or softened bones. ARHR2 and osteomalacia cause pain and difficulty with movement. Additionally, patients may experience hearing loss, calcification in arteries and joints, and heart problems. ENPP1 Deficiency is an autosomal recessive disease and biallelic mutations are estimated to occur in approximately 1 in 64,000 pregnancies worldwide. Many individuals with just one copy of the mutated gene (monoallelic ENPP1 Deficiency) exhibit severe symptoms, suggesting that the worldwide prevalence of ENPP1 Deficiency may be much higher than current estimates. Currently, there are no approved therapies for ENPP1 Deficiency.
About Inozyme Pharma
Inozyme Pharma is a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics that target the PPi-Adenosine Pathway, a key regulator of bone health and blood vessel function. Disruptions in this pathway underlie a range of severe diseases, including ENPP1 Deficiency. Our lead investigational therapy, INZ-701, is an ENPP1 Fc fusion protein enzyme replacement therapy (ERT) designed to restore PPi and adenosine levels. INZ-701 is currently in late-stage clinical development in ENPP1 Deficiency, with the potential to expand into additional indications where deficiencies in the PPi-Adenosine Pathway contribute to disease pathology. Through our pioneering work, we aim to transform treatment options for patients affected by these devastating conditions.
For more information, please visit https://www.inozyme.com/ or follow Inozyme on LinkedIn, X, and Facebook.
Condensed Consolidated Balance Sheet
(in thousands)
December 31, 2024 December 31, 2023
Cash, cash equivalents and investments $ 113,087 $ 188,289
Total assets 123,182 200,847
Total liabilities 65,356 60,368
Additional paid-in-capital 445,705 426,362
Accumulated deficit (387,954) (285,930)
Total stockholders' equity 57,826 140,479
Condensed Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share and per share data)
Year Ended December 31,
2024 2023
Operating expenses:
Research and development $ 83,231 $ 54,847
General and administrative 20,799 20,798
Total operating expenses 104,030 75,645
Loss from operations (104,030) (75,645)
Other income (expense):
Interest income 7,666 7,837
Interest expense (5,558) (3,333)
Other expense, net (102) (28)
Other income, net 2,006 4,476
Net loss $ (102,024) $ (71,169)
Other comprehensive income (loss):
Unrealized gains on available-for-sale securities 24 264
Foreign currency translation adjustment 4 (18)
Total other comprehensive income 28 246
Comprehensive loss $ (101,996) $ (70,923)
Net loss attributable to common stockholders—basic
and diluted
$ (102,024) $ (71,169)
Net loss per share attributable to common
stockholders—basic and diluted
$ (1.62) $ (1.37)
Weighted-average common shares outstanding—basic
and diluted
62,811,814 51,839,131
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute 'forward-looking statements' within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the initiation, timing, and design of our planned clinical trials, enrollment and availability of data from clinical trials, the potential benefits of INZ-701, our regulatory strategy and our strategic prioritization and the period over which we believe that our existing cash, cash equivalents and short-term investments will be sufficient to fund our cash flow requirements. The words 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would,' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. These risks and uncertainties include, but are not limited to, risks associated with the Company's ability to realize the anticipated cost savings related to the strategic prioritization and workforce reduction; conduct its ongoing clinical trials of INZ-701 for ENPP1 Deficiency, ABCC6 Deficiency, and calciphylaxis; enroll patients in ongoing and planned trials; obtain and maintain necessary approvals from the FDA and other regulatory authorities; continue to advance its product candidates in preclinical studies and clinical trials; replicate in later clinical trials positive results found in preclinical studies and early-stage clinical trials of its product candidates; advance the development of its product candidates under the timelines it anticipates in planned and future clinical trials; obtain, maintain, and protect intellectual property rights related to its product candidates; manage expenses; comply with covenants under its outstanding loan agreement; and raise the substantial additional capital needed to achieve its business objectives. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the 'Risk Factors' section in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as well as discussions of potential risks, uncertainties, and other important factors, in the Company's most recent filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof and should not be relied upon as representing the Company's views as of any date subsequent to the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.
Contacts
Media:
Biongage Communications
Todd Cooper
(617) 840-1637

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

LEADING EDGE MATERIALS ANNOUNCES UP TO $4,000,000 NON-BROKERED PRIVATE PLACEMENT
LEADING EDGE MATERIALS ANNOUNCES UP TO $4,000,000 NON-BROKERED PRIVATE PLACEMENT

Hamilton Spectator

time26 minutes ago

  • Hamilton Spectator

LEADING EDGE MATERIALS ANNOUNCES UP TO $4,000,000 NON-BROKERED PRIVATE PLACEMENT

LEADING EDGE MATERIALS ANNOUNCES UP TO C$4,000,000 NON-BROKERED PRIVATE PLACEMENT NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAWS. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER, OR A SOLICITATION OF ANY OFFER, TO BUY OR SUBSCRIBE FOR ANY SECURITIES IN LEADING EDGE MATERIALS IN ANY JURISDICTION. Vancouver, June 10, 2025 – Leading Edge Materials Corp. ('Leading Edge Materials' or the 'Company') (TSXV: LEM) (Nasdaq First North: LEMSE) (OTCQB: LEMIF) announces the intent to complete a non-brokered private placement of up to 25,000,000 units ('Units') at a price of C$0.16 per Unit for aggregate gross proceeds of up to C$4,000,000 (the 'Private Placement'). Leading Edge Materials intends to use net proceeds for the Company's projects, located in Sweden and Romania and for general working capital and corporate purposes. Each Unit will consist of one (1) common share (each, a 'Common Share') in the capital of the Company and one (1) Common Share purchase warrant (a 'Warrant'). Each Warrant will entitle the holder to purchase one Common Share (a 'Warrant Share') at a price of C$0.32 per Warrant Share until the date which is four (4) years from the closing date of the Private Placement (the 'Closing Date'). The Company expects certain insiders of the Company to participate in the Private Placement. Any participation by insiders in the Private Placement constitutes a 'related party transaction' as defined under Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions ('MI 61-101'). However, the Company expects to rely on exemptions from the formal valuation and minority shareholder approval requirements of MI 61-101 based on the fact that neither the fair market value of the Units subscribed for by the insiders, nor the consideration for the Units paid by such insiders, would exceed 25% of the Company's market capitalization as at the date of this news release. The Private Placement is directed towards Canadian, Nordic and other international investors. All securities issued under the Private Placement, including securities issuable on exercise of the Warrants, will be delivered from Canada and are subject to a hold period expiring four months and one day from the Closing Date. The Private Placement is subject to certain conditions including, but not limited to, the receipt of all necessary regulatory approvals, including the approval of the TSX Venture Exchange. A finders' fees may be payable on a portion of the Private Placement. The securities have not been, and will not be, registered under the U.S. Securities Act, or any U.S. state securities laws, and may not be offered or sold in the U.S. or to, or for the account or benefit of, United States persons absent registration or an applicable exemption from the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. This press release shall not constitute an offer to sell or the solicitation of an offer to buy securities in the United States, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. This news release is not a prospectus under Regulation (EU) 2017/1129 (the 'EU Prospectus Regulation'). The Company has not authorized any offer of securities to the public (as defined in the EU Prospectus Regulation) in any EEA member state and no such prospectus has been or will be prepared in connection with the Private Placement. On behalf of the Board of Directors, Leading Edge Materials Corp. Kurt Budge, CEO For further information, please contact the Company at: info@ Follow us Twitter: Linkedin: About Leading Edge Materials Leading Edge Materials is a Canadian public company focused on developing a portfolio of critical raw material projects located in the European Union. Critical raw materials are determined as such by the European Union based on their economic importance and supply risk. They are directly linked to high growth technologies such as batteries for electromobility and energy storage and permanent magnets for electric motors and wind power that underpin the clean energy transition towards climate neutrality. The portfolio of projects includes the 100% owned Woxna Graphite mine (Sweden), 100% owned Norra Karr Heavy Rare Earth Elements project (Sweden) and the 51% owned Bihor Sud Nickel Cobalt exploration alliance (Romania). Additional Information This information is information that Leading Edge Materials Corp. is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, at June 10, 2025 at 23:30 PM Vancouver time. Leading Edge Materials is listed on the TSXV under the symbol 'LEM', OTCQB under the symbol 'LEMIF' and Nasdaq First North Stockholm under the symbol 'LEMSE'. Mangold Fondkommission AB is the Company's Certified Adviser on Nasdaq First North and may be contacted via email CA@ or by phone +46 (0) 8 5030 1550. Reader Advisory This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in Leading Edge Materials in any jurisdiction. This news release may include forward-looking information that is subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward-looking, including statements with respect to the closing of the Private Placement, the receipt of regulatory approvals, and the use of proceeds from the Private Placement. Although the Company believes the expectations expressed in such forward-looking information are based on reasonable assumptions, such information is not a guarantee of future performance and actual results or developments may differ materially from those contained in forward-looking information. Factors that could cause actual results to differ materially from those in forward-looking information include, but are not limited to, fluctuations in market prices, successes of the operations of the Company, the Company's ability to close the Private Placement, the Company's ability to obtain the required regulatory approvals, continued availability of capital and financing and general economic, market or business conditions. There can be no assurances that such information will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. The Company does not assume any obligation to update any forward-looking information except as required under the applicable securities laws. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Important information for EEA Investors The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions. The recipients of this press release in jurisdictions where this press release has been published or distributed shall inform themselves of and follow such restrictions. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in Leading Edge Materials in any jurisdiction. Any investment decision in connection with the Private Placement must be made on the basis of all publicly available information relating to the Company and the Company's shares/Units. The information contained in this announcement is for background purposes only and does not purport to be full or complete. No reliance may be placed for any purpose on the information contained in this announcement or its accuracy or completeness. This announcement does not purport to identify or suggest the risks (direct or indirect) which may be associated with an investment in the Company or the new shares/Units. This press release is not a prospectus for the purposes of the EU Prospectus Regulation. Leading Edge Materials has not authorized any offer to the public of Units, shares or rights in any member state of the EEA and no prospectus has been or will be prepared in connection with the Private Placement. In the United Kingdom, this document and any other materials in relation to the securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, 'qualified investors' who are (i) persons having professional experience in matters relating to investments who fall within the definition of 'investment professionals' in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the 'Order'); or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as 'relevant persons'). In the United Kingdom, any investment or investment activity to which this communication relates is available only to, and will be engaged in only with, relevant persons. Persons who are not relevant persons should not take any action on the basis of this document and should not act or rely on it. Attachment

tpay Releases White Paper on the Transformative Power of Open Banking Across the Middle East
tpay Releases White Paper on the Transformative Power of Open Banking Across the Middle East

Yahoo

time2 hours ago

  • Yahoo

tpay Releases White Paper on the Transformative Power of Open Banking Across the Middle East

DUBAI, United Arab Emirates, June 11, 2025 (GLOBE NEWSWIRE) -- tpay, the leading payment connector in the META region, has published a new white paper highlighting how Open Banking is accelerating financial innovation and inclusion across the region. The white paper explores the rapid rise of fintech in the Middle East, where updated licensing frameworks and increased investment are driving significant growth. Despite lower valuations compared to Western markets, the region offers immense profit potential for fintech players, digital banks, and regulators alike. With Open Banking unlocking new use cases and creating seamless digital experiences for consumers and businesses, the white paper outlines the strategic importance of the Middle East in the global financial ecosystem. The region is poised to play a key role in the expected surge of digital payment adoption, with global digital wallet users projected to exceed 5.2 billion by 2026, up from 3.4 billion in 2022, marking robust growth of over 53%. Download the full white paper to explore how Open Banking is reshaping the financial landscape in the Middle East. Open Banking: A Game Changer In the Middle East CONTACT: For more information, please contact: in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

All Seas Capital Exits G3
All Seas Capital Exits G3

Yahoo

time2 hours ago

  • Yahoo

All Seas Capital Exits G3

Realisation follows significant growth with headcount doubling and international expansion LONDON, June 11, 2025--(BUSINESS WIRE)--All Seas Capital, a pan-European private capital fund that provides transformational capital solutions to leading founder- and entrepreneur-owned companies, is pleased to announce the full realisation of its investment in G3 ("G3" or "the Company"), a global strategic advisory consultancy. As part of the transaction, Oakley Capital Fund VI has acquired a majority stake in the Company. G3 helps clients manage their risk and enable opportunities by providing reputational and strategic intelligence, dispute advice and cyber consulting. The company's clients include some of the largest private equity and sovereign wealth funds, global corporates and leading law firms. Since investing in G3 in 2022, All Seas Capital has partnered closely with the management team to accelerate its expansion strategies. G3 has grown significantly, with headcount more than doubling and global business development capabilities strengthened, with the opening of new offices in New York, Singapore, Tokyo, and Abu Dhabi. All Seas Capital provides flexible long-term capital solutions to leading Western European mid-market businesses. Alongside transformational capital, the firm provides board-level expertise to entrepreneurs and management teams who do not want to sell majority stakes. All Seas Capital is led by Marc Ciancimino and Cristobal Cuart, who co-founded and led KKR's European mezzanine and preferred equity business and have an extensive track record, with €3.4bn invested across 45 businesses prior to founding All Seas Capital. Marc Ciancimino and Cristobal Cuart, Co-Founders and Managing Partners of All Seas Capital, commented: "Since partnering with G3 three years ago, we have worked hard to support its highly capable management team to accelerate its expansion strategies and develop the business. It has achieved great success, capitalising on the significant growth in demand for strategic risk advisory services. At All Seas Capital, we provide flexible, hybrid non-control capital to established founder- and entrepreneur-owned businesses that have already reached scale and can benefit from our support and capital. G3 is a great example of how our approach can support that journey, and we wish the team every success with their new partners at Oakley Capital." All Seas Capital was advised by King & Spalding. G3 was advised by Jefferies, White & Case. LEK and KPMG. About All Seas Capital All Seas Capital is a pan-European private capital firm. We partner with mid-market businesses, constructing flexible, structured capital solutions - investing a combination of debt and equity - to empower transformational growth. The team is led by Marc Ciancimino and Cristobal Cuart who co-founded and led KKR's European mezzanine and preferred equity business. We back growing businesses with strong management teams and help them accelerate their growth plans, supporting entrepreneur and family-owned businesses who have already reached profitability but need strategic capital to realise their ambitions. These businesses have underlying resilience, typically generating EBITDA of €5-50m, with our investment ranging from €30-100m. About G3 G3 is a global advisory firm that helps clients manage risk and make better business decisions. We provide intelligence that enables our clients to make informed decisions on deals, partnerships, new markets, and regulatory and political environments. We offer investigations and dispute advice to support legal strategies and recover assets. We deliver cyber-security advice to defend against today's prevailing threat environment. Our clients include FTSE and Fortune 500 corporations, sovereign wealth and pension funds, private equity firms, and leading international law firms. Founded over twenty years ago, G3 has an established global platform and operates in most geographies worldwide. Our multidisciplinary team is drawn from government, finance, law, consultancy, and law enforcement. We are headquartered in London, with offices in the US, the Middle East, and Asia. View source version on Contacts For further information, please contact: All Seas CapitalCharlotte Balbirnie+44 7989 528421CBalbirnie@

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store